- Home
- CVM vs BRTX Comparison
CVM vs BRTX Comparison
Compare CVM & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVM
- BRTX
- Stock Information
- Founded
- CVM 1983
- BRTX 1997
- Country
- CVM United States
- BRTX United States
- Employees
- CVM N/A
- BRTX N/A
- Industry
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- BRTX Managed Health Care
- Sector
- CVM Health Care
- BRTX Health Care
- Exchange
- CVM Nasdaq
- BRTX Nasdaq
- Market Cap
- CVM 11.8M
- BRTX 12.6M
- IPO Year
- CVM 1987
- BRTX N/A
- Fundamental
- Price
- CVM $3.46
- BRTX $1.60
- Analyst Decision
- CVM
- BRTX Strong Buy
- Analyst Count
- CVM 0
- BRTX 1
- Target Price
- CVM N/A
- BRTX $18.00
- AVG Volume (30 Days)
- CVM 1.6M
- BRTX 151.8K
- Earning Date
- CVM 08-14-2025
- BRTX 08-12-2025
- Dividend Yield
- CVM N/A
- BRTX N/A
- EPS Growth
- CVM N/A
- BRTX N/A
- EPS
- CVM N/A
- BRTX N/A
- Revenue
- CVM N/A
- BRTX $391,000.00
- Revenue This Year
- CVM N/A
- BRTX $391.52
- Revenue Next Year
- CVM N/A
- BRTX $3.50
- P/E Ratio
- CVM N/A
- BRTX N/A
- Revenue Growth
- CVM N/A
- BRTX 161.54
- 52 Week Low
- CVM $1.98
- BRTX $1.21
- 52 Week High
- CVM $66.60
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- CVM 57.66
- BRTX 45.93
- Support Level
- CVM $2.24
- BRTX $1.51
- Resistance Level
- CVM $2.71
- BRTX $1.79
- Average True Range (ATR)
- CVM 0.51
- BRTX 0.10
- MACD
- CVM 0.25
- BRTX -0.00
- Stochastic Oscillator
- CVM 25.61
- BRTX 32.14
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.